Publications

1. ADEPT, Airway Disease Endotyping for Personalized Treatment: Interim Analysis of Asthma Patients
M. Loza; I. Strambu, MD; M. Laviolette, MD; D. Singh, MD; J.M. Fitzgerald, MD; S. Kelsen, MD; A. Eich, MD; A. Ludwig-Sengpiel, MD; G. Chupp, MD; C. Porsbjerg, MD; P. Berger, MD; R. Leigh, MD; J. Kline, MD; M. Dransfield, MD; W. Calhoun, MD; A. Hussaini; P. Chanez, MD; V.S. Susulic; P.E. Silkoff, MD and F. Baribaud
ERS 2013, Poster Presentation

2. Use of a portable device to record maximum inspiratory flow in relation to dyspnoea in patients with COPD. 
Taube C, Rydzy L, Eich A, Korn S, Kornmann O, Sebastian M, Jörres RA, Buhl R.
Respir Med. 2011 Feb;105(2):316-21. Epub 2010 Dec 9.

3. Measurement of exhaled nitric oxide: comparison of different analysers.
Korn S, Telke I, Kornmann O, Buhl R.
Respirology. 2010 Nov;15(8):1203-8. doi: 10.1111/j.1440-1843.2010.01847.x.

4. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison.
Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B; INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-µg Doses with COPD Patients) study investigators.
Eur Respir J. 2011 Feb;37(2):273-9. Epub 2010 Aug 6.

5. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany.  
Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R.
Respir Med. 2009 Nov;103(11):1725-31. Epub 2009 Jun 9.

6. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma.  
Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlén SE, Holgate ST, Meyers DA, Rabe KF, Antczak A, Baker J, Horvath I, Mark Z, Bernstein D, Kerwin E, Schlenker-Herceg R, Lo KH, Watt R, Barnathan ES, Chanez P; T03 Asthma Investigators.  
Am J Respir Crit Care Med. 2009 Apr 1;179(7):549-58. Epub 2009 Jan 8.

7. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, Stenglein S, Seyfried S, Wahn U; DUAL study group.  
Clin Exp Allergy. 2009 Feb;39(2):271-9. Epub 2008 Oct 30.

8. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.  
Rennard S, Bantje T, Centanni S, Chanez P, Chuchalin A, D'Urzo A, Kornmann O, Perry S, Jack D, Owen R, Higgins M.  
Respir Med. 2008 Jul;102(7):1033-44. Epub 2008 May 13.

9. Effect of the oral leukotriene B4 receptor antagonist LTB019 on inflammatory sputum markers in patients with chronic obstructive pulmonary disease.  
Grönke L, Beeh KM, Cameron R, Kornmann O, Beier J, Shaw M, Holz O, Buhl R, Magnussen H, Jörres RA.  
Pulm Pharmacol Ther. 2008;21(2):409-17. Epub 2007 Nov 9.

10. Discrepant nasal and bronchial nitric oxide kinetics during early and late phase allergic reactions.  
Korn S, Beier J, Heilmann C, Kornmann O, Buhl R, Michael Beeh K.  
Respir Med. 2005 Dec;99(12):1595-9. Epub 2005 Apr 26.

11. Induced sputum methodology: Validity and reproducibility of total glutathione measurement in supernatant of healthy and asthmatic individuals.  
Beier J, Beeh KM, Kornmann O, Buhl R.
J Lab Clin Med. 2004 Jul;144(1):38-44.